Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

Aim. To assess the efficacy and safety of using the drug Extimia BIOCAD (international nonproprietary name INN: empegfilgrastim) in order to reduce the frequency and duration of neutropenia, the frequency of febrile neutropenia (FN) and infections manifested by FN in patients with lymphoproliferati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, Natalya N. Glonina, Natalya V. Fadeeva, Tatyana A. Sannikova, Irina S. Lyalina, Tatyana V. Shelekhova, Dmitrij G. Sherstnev, Sergey V. Voloshin, Vladislav O. Sarzhevskii, Alina A. Hofman, Damir G. Ichshanov, Irina V. Poddubnaya
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2021
Materias:
non-hodgkin’s lymphoma
empegfilgrastim
pegylated colony-stimulating factor
clinical practice
prevention of neutropenia
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/f8ac47889d5d41f7a8c9e2650cc5399d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f8ac47889d5d41f7a8c9e2650cc5399d

Ejemplares similares